PMID- 34313333
OWN - NLM
STAT- MEDLINE
DCOM- 20210915
LR  - 20210915
IS  - 1365-2036 (Electronic)
IS  - 0269-2813 (Linking)
VI  - 54
IP  - 6
DP  - 2021 Sep
TI  - Systematic review: duodenogastroesophageal (biliary) reflux prevalence, symptoms, 
      oesophageal lesions and treatment.
PG  - 755-778
LID - 10.1111/apt.16533 [doi]
AB  - BACKGROUND: The prevalence of duodenogastroesophageal reflux (DGER) and its 
      effect on symptoms and oesophageal lesions in gastroesophageal reflux disease 
      (GERD) is unclear. AIMS: To conduct a systematic review to determine the 
      prevalence of DGER among patients with GERD, the effect of DGER on symptoms and 
      oesophageal lesions, and the treatment of DGER. METHODS: We searched Pubmed and 
      MEDLINE for full text, English language articles until October 2020 that 
      evaluated DGER prevalence among patients with GERD, the effect of DGER on 
      symptoms and oesophageal lesions, and the treatment of DGER. RESULTS: We 
      identified 3891 reports and included 35 which analysed DGER prevalence in GERD, 
      15 which evaluated its effect in non-erosive reflux disease (NERD), 17 on erosive 
      oesophagitis, 23 in Barrett's, and 13 which evaluated the treatment of DGER. The 
      prevalence of DGER, when evaluated by Bilitec, among all GERD patients ranged 
      from 10% to 97%, in NERD 10%-63%, in erosive oesophagitis 22%-80% and in 
      Barrett's 50%-100%. There were no differences in the presence or degree of DGER 
      among patients who were asymptomatic or symptomatic on proton pump inhibitors 
      (PPI). The most commonly evaluated treatments for DGER were PPIs and DGER reduced 
      post-PPI therapy in all studies. CONCLUSIONS: The prevalence of DGER increased 
      with more advanced oesophageal lesions and did not explain persisting symptoms 
      among patients taking PPI therapy. PPIs appear to be effective in the treatment 
      of DGER. DGER remains an important consideration in patients with GERD and future 
      therapies deserve more study.
CI  - (c) 2021 John Wiley & Sons Ltd.
FAU - Basnayake, Chamara
AU  - Basnayake C
AUID- ORCID: 0000-0001-6103-769X
AD  - Department of Chronic Diseases, Metabolism and Ageing (ChroMetA), Translational 
      Research Center for Gastrointestinal Disorders (TARGID), Katholieke Universiteit 
      Leuven, Leuven, Belgium.
AD  - St Vincent's Hospital & University of Melbourne, Melbourne, VIC, Australia.
FAU - Geeraerts, Annelies
AU  - Geeraerts A
AD  - Department of Chronic Diseases, Metabolism and Ageing (ChroMetA), Translational 
      Research Center for Gastrointestinal Disorders (TARGID), Katholieke Universiteit 
      Leuven, Leuven, Belgium.
FAU - Pauwels, Ans
AU  - Pauwels A
AD  - Department of Chronic Diseases, Metabolism and Ageing (ChroMetA), Translational 
      Research Center for Gastrointestinal Disorders (TARGID), Katholieke Universiteit 
      Leuven, Leuven, Belgium.
FAU - Koek, Ger
AU  - Koek G
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
      Maastricht University Medical Center, Maastricht, The Netherlands.
FAU - Vaezi, Michael
AU  - Vaezi M
AD  - Vanderbilt University Medical Center, Nashville, TN, USA.
FAU - Vanuytsel, Tim
AU  - Vanuytsel T
AUID- ORCID: 0000-0001-8728-0903
AD  - Department of Chronic Diseases, Metabolism and Ageing (ChroMetA), Translational 
      Research Center for Gastrointestinal Disorders (TARGID), Katholieke Universiteit 
      Leuven, Leuven, Belgium.
FAU - Tack, Jan
AU  - Tack J
AUID- ORCID: 0000-0002-3206-6704
AD  - Department of Chronic Diseases, Metabolism and Ageing (ChroMetA), Translational 
      Research Center for Gastrointestinal Disorders (TARGID), Katholieke Universiteit 
      Leuven, Leuven, Belgium.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20210727
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - *Duodenogastric Reflux
MH  - *Esophagitis, Peptic
MH  - *Gastroesophageal Reflux/drug therapy/epidemiology
MH  - Humans
MH  - Prevalence
MH  - Proton Pump Inhibitors/therapeutic use
EDAT- 2021/07/28 06:00
MHDA- 2021/09/16 06:00
CRDT- 2021/07/27 08:49
PHST- 2021/05/20 00:00 [revised]
PHST- 2021/04/18 00:00 [received]
PHST- 2021/07/01 00:00 [accepted]
PHST- 2021/07/28 06:00 [pubmed]
PHST- 2021/09/16 06:00 [medline]
PHST- 2021/07/27 08:49 [entrez]
AID - 10.1111/apt.16533 [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2021 Sep;54(6):755-778. doi: 10.1111/apt.16533. Epub 2021 
      Jul 27.